BRAIN Biotech AG

XETRA BNN.DE

BRAIN Biotech AG Price to Earnings Ratio (P/E) on January 14, 2025: -9.34

BRAIN Biotech AG Price to Earnings Ratio (P/E) is -9.34 on January 14, 2025, a 3.71% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • BRAIN Biotech AG 52-week high Price to Earnings Ratio (P/E) is -4.05 on September 12, 2024, which is 56.58% above the current Price to Earnings Ratio (P/E).
  • BRAIN Biotech AG 52-week low Price to Earnings Ratio (P/E) is -12.06 on December 12, 2024, which is -29.20% below the current Price to Earnings Ratio (P/E).
  • BRAIN Biotech AG average Price to Earnings Ratio (P/E) for the last 52 weeks is -7.59.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
XETRA: BNN.DE

BRAIN Biotech AG

CEO Mr. Adriaan Moelker
IPO Date Feb. 9, 2016
Location Germany
Headquarters Darmstädter Strasse 34-36
Employees 319
Sector Health Care
Industries
Description

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

Similar companies

FYB.DE

Formycon AG

USD 60.50

-1.24%

COP.DE

CompuGroup Medical SE & Co. KGaA

USD 22.41

0.70%

MDG1.DE

Medigene AG

USD 1.09

3.54%

StockViz Staff

January 15, 2025

Any question? Send us an email